Cinclus Pharma Partners with Zentiva in €220M Deal to Commercialize Linaprazan Glurate in Europe

Cinclus Pharma, a clinical-stage biopharma company developing treatments for acid-related diseases, has entered a major licensing and commercialization agreement with European pharmaceutical leader Zentiva. The deal, valued at up to €220 million, grants Zentiva exclusive rights to manufacture and market Cinclus’s lead asset, linaprazan glurate, across the EEA, UK, and Switzerland.

Linaprazan glurate is a next-generation treatment for severe erosive GERD, targeting a European and US market of approximately 10 million patients.

This strategic partnership strengthens Cinclus Pharma’s commercialization pathway in Europe while retaining full rights to the US market, positioning the company for significant global value creation.